Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

British Journal of Dermatology

Volumn 173, Issue 4, 2015, Pages 930-939

  Papp, K ^a   Thaci D ^b   Reich, K ^c   Riedl, E ^d   Langley, R G ^e   Krueger, J G ^f   Gottlieb, A B ^g   Nakagawa, H ^h   Bowman, E P ⁱ   Mehta, A ⁱ   Li, Q ⁱ   Zhou, Y ⁱ   Shames, R ⁱ  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b UNIVERSITY OF LÜBECK   (Germany)

^c Dermatologikum Hamburg and SCIderm Research Institute   (Germany)

^d Universitatsklinik fur Dermatologie   (Austria)

^e DALHOUSIE UNIVERSITY   (Canada)

^f ROCKEFELLER UNIVERSITY   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TILDRAKIZUMAB; DERMATOLOGICAL AGENT; INTERLEUKIN 23P19; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; ALLERGIC REACTION; APPENDICITIS; ARTHRALGIA; ARTICLE; BACKACHE; BACTERIAL ARTHRITIS; BORDERLINE HYPERTENSION; BRAIN ISCHEMIA; BURSITIS; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CHRONIC PLAQUE PSORIASIS; CLINICAL EVALUATION; CONTROLLED STUDY; CONTUSION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EPIGLOTTITIS; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE REACTION; KNEE DISEASE; LIMB FRACTURE; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVARY CYST; PHASE 2 CLINICAL TRIAL; PHOTOTHERAPY; PLACEBO EFFECT; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SURGICAL INFECTION; SYSTEMIC THERAPY; TENDON RUPTURE; TREATMENT RESPONSE; VITAL SIGN; ADOLESCENT; AGED; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-23 SUBUNIT P19; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945443119     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13932     Document Type: Article

References (25)

1. Krueger G, Koo J, Lebwohl M, et al,. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
2. Bansback N, Sizto S, Sun H, et al,. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219: 209-18.
3. Nijsten T, Margolis DJ, Feldman SR, et al,. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434-44.
4. Stern RS, Nijsten T, Feldman SR, et al,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
5. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
6. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
7. Papp KA, Sundaram M, Bao Y, et al,. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 2013; 28: 790-8.
8. Gordon KB, Langley RG, Gottlieb AB, et al,. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132: 304-14.
9. Chan JR, Blumenschein W, Murphy E, et al,. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-87.
10. Nair RP, Duffin KC, Helms C, et al,. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199-204.
11. Kopp T, Riedl E, Bangert C, et al,. Clinical improvement in psoriasis with specific targeting of interleukin (IL)-23. Nature 2015; 521: 222-6.
12. Sofen H, Smith S, Matheson RT, et al,. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133: 1032-40.
13. Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
14. Wilson NJ, Boniface K, Chan JR, et al,. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
15. Hueber W, Patel DD, Dryja T, et al,. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
16. Krueger JG, Fretzin S, Suarez-Farinas M, et al,. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130: 145-54.
17. Tonel G, Conrad C, Laggner U, et al,. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010; 185: 5688-91.
18. Chackerian AA, Chen SJ, Brodie SJ, et al,. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 2006; 74: 6092-9.
19. Kagami S, Rizzo HL, Kurtz SE, et al,. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010; 185: 5453-62.
20. Schulz SM, Kohler G, Schutze N, et al,. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol 2008; 181: 7891-901.
21. Teng MW, Vesely MD, Duret H, et al,. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012; 72: 3987-96.
22. Grivennikov SI, Wang K, Mucida D, et al,. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-8.
23. Jantschitsch C, Weichenthal M, Proksch E, et al,. IL-12 and IL-23 affect photocarcinogenesis differently. J Invest Dermatol 2012; 132: 1479-86.
24. Langowski JL, Zhang X, Wu L, et al,. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-5.
25. Maeda A, Schneider SW, Kojima M, et al,. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 2006; 66: 2962-9.